Selling to Cencora

Cencora reported 321.3 billion dollars of revenue in fiscal 2025, the year ended 30 September 2025, and employs more than 51,000 people worldwide. The number that should shape your plan is the one underneath it: the U.S. Healthcare Solutions segment turned 291.0 billion dollars of revenue into 3.57 billion dollars of segment operating income, a margin of 1.23 percent.

That single line is the commercial reality of the account. Cencora is neither a payer nor a provider. It moves other companies' products and keeps a little over a cent of operating profit on each dollar. Any recurring cost you propose lands on that spread, and whoever defends your line item internally knows what it does to the margin they are measured on.

A second fact matters before the first meeting. Effective 1 October 2025 Cencora changed its reporting structure, moving from two reportable segments to three parts: U.S. Healthcare Solutions, International Healthcare Solutions, and a bucket called Other. Cencora states that Other consists of businesses for which it has begun to explore strategic alternatives, and names them: MWI Animal Health, Profarma, U.S. Consulting Services and other components of PharmaLex. If your opportunity originates inside one of those, you are proposing a multi year commitment to a business whose owner may change. Establish that before you build a forecast.

The rename is a practical problem, not a cosmetic one

AmerisourceBergen became Cencora and began trading under the ticker COR on the New York Stock Exchange on 30 August 2023. That matters in three ways. Legacy master agreements and purchase orders in your files still carry the old name. Your CRM almost certainly holds two records for one account, which fragments your view of who has already touched it. And the people most useful to you, the ones who left in 2019 or 2021 and still know everyone inside, describe themselves publicly as AmerisourceBergen alumni, so a search on the current name misses them. Run both names across every list you own before concluding you have no route in.

How the buying process actually runs

There are separate front doors and they are not interchangeable. Direct suppliers, meaning manufacturers whose product moves through the distribution network and is resold, transact through the Cencora Supplier Portal. Indirect suppliers, meaning everything Cencora buys to run itself, are served by a separate Supplier Support Center for indirect procurement, which Cencora describes as providing legal contracting documents, compliance guidance and Ariba guidance. A third route, cencora.supplierone.co, handles small and diverse business registration, and Cencora states that a submission does not guarantee a business opportunity. Registration is a prerequisite, not a pipeline.

The paperwork starts earlier than most sellers expect. Cencora publishes a supplier code of conduct, minimum insurance requirements with a certificate required before work commences, EU controller to processor transfer clauses, and separate general terms for the United States, India and Costa Rica. Those last two hint at where shared services and technology delivery sit.

Controlled substances change the shape of diligence. Cencora reports controlled substance transactions to the Drug Enforcement Administration daily and has a named Chief Diversion Control Officer, a role most companies its size do not staff. Distribution of opioid medicines is less than one percent of annual revenue, but the compliance machinery around it is not proportional to that and it reaches into order data, warehouse systems and reporting. If your product touches those, compliance joins the first technical call rather than the contract stage.

Who owns what, so you know where your deal belongs

You will not be selling to these people. Their remits tell you which part of the business your deal sits in, and whose priorities it must survive two or three levels down.

Robert P. Mauch, PharmD, PhD, has been President and Chief Executive Officer since October 2024, having previously been Chief Operating Officer. He founded Xcenda, acquired by the company in 2007, so the chief executive is himself a small vendor that ended up inside the account. Names taken from Cencora's leadership page and its 2026 proxy statement, verified 11 September 2026. Verify at source before using any name.

Why you cannot sell into this account from the bottom

Run the arithmetic from Cencora's side. A one million dollar annual commitment is assessed against a segment that produced 3.57 billion dollars of operating income on 291.0 billion dollars of revenue. In a business with normal gross margins that is a rounding error. In a distributor running near one percent operating margin it is a visible claim on the number the segment is judged by, so approval sits higher than the deal size alone would suggest anywhere else.

That is the trap. The quickest replies come from people who cannot approve the spend, so the buying committee you assemble starts higher than your price tag implies.

The layer that matters sits below the published names

Eight people appear on Cencora's enterprise leadership page. They are easy to name and are not your sponsors.

The sponsors sit a level or two down, and that layer is split in a way unusual for a company this size. It is operational in the United States: people running distribution service centres, the national distribution centre in Columbus, Ohio, and the second being built at Harrison, Ohio under a one billion dollar investment through 2030 to expand capacity and cold chain storage. It is also genuinely international: Alliance Healthcare country leaders in Europe, Innomar in Canada, and World Courier. Cencora did not exit Europe, it reorganised around it, so your decision maker may sit in a market with its own regulator and procurement custom. None of these people appear on a published page, which is why the map is hard to draw from outside.

The board is a published second degree map

This is the most useful asset here: public, checkable and almost nobody uses it. Cencora's eleven director nominees in the 2026 proxy statement, and where else they sit:

• D. Mark Durcan, independent Chair since 1 October 2025, formerly CEO of Micron Technology. Current public board: ASML Holding.
• Werner Baumann, Audit Committee chair, formerly CEO and Chairman of the Board of Management of Bayer AG until May 2023. No other current public board.
• Dennis M. Nally, Compensation Committee chair, formerly Chairman of PricewaterhouseCoopers International. Current public board: Morgan Stanley.
• Ellen G. Cooper, elected January 2026, currently Chairman, President and CEO of Lincoln National Corporation.
• Lori J. Ryerkerk, elected June 2025, formerly CEO and chair of Celanese until December 2024. Current public boards: Eaton and Norfolk Southern.
• Frank K. Clyburn, formerly CEO of International Flavors and Fragrances and before that President of Human Health at Merck. Current public board: Revolution Medicines.
• Lorence H. Kim, M.D., formerly CFO of Moderna, now at venture firm Ascenta Capital. Current public board: Revolution Medicines.
• Redonda G. Miller, M.D., Compliance and Risk Committee chair, currently President of The Johns Hopkins Hospital.
• Lon R. Greenberg, formerly Chairman and CEO of UGI Corporation, currently Chairman of Temple University Health System.
• Lauren M. Tyler, formerly Global Head of Human Resources at J.P. Morgan Asset and Wealth Management until 2024, currently a director of Guardian Life.
• Robert P. Mauch, President and CEO of Cencora.

Read that as a seller and notice what it is. This is not a healthcare board. It is weighted towards semiconductors, chemicals, industrials and audit: Micron, ASML, Bayer, Celanese, Eaton, Norfolk Southern, UGI, PwC, Morgan Stanley and Lincoln National. Two directors, Clyburn and Kim, sit together on Revolution Medicines, so one relationship there reaches two Cencora directors. If anyone in your network is senior at those organisations, or at The Johns Hopkins Hospital, Temple University Health System or Guardian Life, you have a checkable two hop path rather than a hypothetical one.

Other connector routes into this account

Alumni under both names. Cencora runs no formal public alumni programme, so the substitute is your own data, searched for AmerisourceBergen as well as Cencora. Add acquired company alumni: Retina Consultants of America closed on 2 January 2025, and Xcenda, World Courier, MWI Animal Health, Alliance Healthcare and PharmaLex all arrived by acquisition. The PharmaLex and MWI populations are especially reachable given the strategic alternatives review.

Both ends of the chain. Walgreens and Boots together accounted for approximately 25 percent of fiscal 2025 revenue and Evernorth Health Services for approximately 13 percent, with the ten largest customers at roughly 66 percent. If you sell to large retail pharmacy or to pharmacy benefit organisations you already share rooms with people who negotiate with Cencora constantly, and a warm referral from that side of the table carries weight no vendor email can. The manufacturers Cencora distributes for are a second connector pool.

Working out which of these paths your company actually has is what a relationship intelligence platform is for. The routes exist. At most companies nobody has run the query, under either name.

The internal ask, and the cost of getting it wrong

The step that fails more introductions is the internal one. Suppose your best path runs through one of your own investors or board members who also sits on a board with a Cencora director. That is close to the strongest route available and close to unrepeatable. You have to get that person to prioritise it, write something credible in their own voice, and spend a piece of a relationship built over years on you. Ask twice in a quarter and you will not be asked again. The same applies to a manufacturer contact or a pharmacy customer. Two of your own representatives approaching the same connector in the same month is common, and invisible unless someone is tracking it.

Three rules for the introduction itself

Ask for the business, not the company. "An introduction to whoever owns indirect technology sourcing for U.S. Pharmaceuticals" is actionable. "An introduction to Cencora" is not, and at an account with businesses under strategic review it may point at the wrong place entirely.

Write the paragraph your connector will forward. They will not write your pitch, and at this margin structure it leads with cost per unit shipped, service levels or compliance exposure, not innovation. The forwardable blurb is the whole craft.

A warm path starts the clock, it does not skip it. You still register, still clear insurance, data protection and security review, and still answer controlled substance questions if your product goes near the supply chain. What it buys you is a real conversation with someone who has the problem and the budget, several quarters earlier than you would otherwise get one.

See the warm paths into Cencora

Everything above describes the problem: three separate supplier doors and a segment under strategic review. What it does not tell you is which of your own relationships already reaches inside. That is a question about your network, not theirs, and it is the one most teams answer from memory.

Boomerang maps the warm paths your company already has into accounts like Cencora, across your team, your customers, your board and investors, and your partners. It then drafts the ask, routes it through the right connector and tracks it to a booked meeting. Book a 15-minute walkthrough and see it run against your own target accounts.